Akashi Therapeutics, Gruenenthal deal

The companies partnered exclusively to develop and commercialize Akashi’s HT-100. Gruenenthal will be responsible for development following Phase II testing and also will develop Akashi’s U.S. commercial infrastructure. Akashi granted Gruenenthal rights to commercialize the compound in Europe and Latin America, but retains rights in the U.S. and other markets. ...